Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRGN-3007

Cell therapy (CAR-T) · Kills target cells, directed at ROR1

Phase 1 Most advanced trial (none active)
1 Registered trials

What is PRGN-3007?

PRGN-3007 is an autologous T-cell therapy engineered with a non-viral transposon to express an anti-ROR1 chimeric antigen receptor, membrane-bound IL-15, a kill switch and intrinsic PD-1 downregulation. The CAR directs the T cells to ROR1-expressing tumor cells for lysis. It is studied in chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
ROR1 (antigen), PD-1 (PDCD1) (secondary target)
Mechanism
Kills target cells, directed at ROR1
Pathways
PD-1 checkpoint signaling, IL-15 signaling
Therapy area
Oncology
In trials of
PGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05694364 Phase 1 Chronic Lymphocytic Leukemia Completed PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaMantle Cell LymphomaTriple Negative Breast Cancer Malignancies

Other drugs acting on ROR1

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.